Chemours (CC) Projected to Post Earnings on Thursday

Chemours (NYSE:CC) is projected to announce its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Chemours to post earnings of $0.01 per share and revenue of $1.3284 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 20, 2026 at 8:00 AM ET.

Chemours Price Performance

Shares of NYSE CC opened at $21.01 on Thursday. The company has a current ratio of 1.71, a quick ratio of 0.88 and a debt-to-equity ratio of 13.66. Chemours has a 52 week low of $9.13 and a 52 week high of $21.09. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -9.47 and a beta of 1.63. The company’s 50-day moving average price is $14.21 and its 200 day moving average price is $14.09.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CC. Zacks Research lowered Chemours from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a report on Wednesday, January 21st. Truist Financial increased their target price on shares of Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 21st. UBS Group lowered their price objective on Chemours from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. cut their price target on Chemours from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Chemours currently has a consensus rating of “Hold” and an average target price of $16.67.

Institutional Investors Weigh In On Chemours

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new position in Chemours during the 3rd quarter worth $43,000. Advisory Services Network LLC bought a new position in Chemours in the third quarter valued at about $54,000. B. Riley Wealth Advisors Inc. bought a new position in Chemours in the 2nd quarter valued at approximately $116,000. Oxford Asset Management LLP acquired a new stake in shares of Chemours during the 2nd quarter valued at $124,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Chemours by 18.9% during the second quarter. Tower Research Capital LLC TRC now owns 12,123 shares of the specialty chemicals company’s stock worth $139,000 after purchasing an additional 1,925 shares during the last quarter. Institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.